Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Retained Earnings (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Retained Earnings data on record, last reported at -$721.6 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 10.24% year-over-year to -$721.6 million; the TTM value through Sep 2025 reached -$721.6 million, up 10.24%, while the annual FY2024 figure was $8000.0, 100.0% up from the prior year.
  • Retained Earnings reached -$721.6 million in Q3 2025 per ABEO's latest filing, down from -$45000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $688.2 million in Q3 2022 and bottomed at -$804.0 million in Q3 2024.
  • Average Retained Earnings over 5 years is -$308.2 million, with a median of -$586.7 million recorded in 2021.
  • The widest YoY moves for Retained Earnings: up 68178200.0% in 2022, down 2575218.52% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$27000.0 in 2021, then plummeted by 2575218.52% to -$695.3 million in 2022, then fell by 7.79% to -$749.5 million in 2023, then surged by 100.0% to $8000.0 in 2024, then tumbled by 9020287.5% to -$721.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$721.6 million in Q3 2025, -$45000.0 in Q2 2025, and -$67000.0 in Q1 2025.